Background:

Biomarkers are currently changing the way we diagnose and treat diseases. Today pharmacodynamic biomarkers are widely used in the industry elaborating optimal dosing of new drugs. At the same time predictive biomarkers have an enormous potential for companion diagnostics.

While elevated cytokine marker concentrations in patients are well documentes, limited data are available for endogenous baseline concentrations for the majority of biomarkers. 

Numerous clinical studies fail due to the lack of reliable data covering

- free circulating biomarker concentration in healthy as well as atients

- relation between applied drug dosage and drug-target-complex formation

- change in biomarker concentration mediated by drug application

Our Offer:

Chimera biotec develops and markets ultra sensitive ligand binding assays based on the immunoPCR (Imperacer®) technology.

Imperacer® quantitatively detects analytes in complex biological samples while extending the dynamic range of an immunoassay by orders of magnitudes.

Increasing the performance of biomarker quantification will increase the significance of the results and furthermore lead to successful clinical studies according to FDA guidelines.

Contact

Chimera Biotec

Dr. Beena Punnamoottil
info(at)chimera-biotec.com
www.chimera-biotec.com
www.imperacer.com
Phone: +49 231 9742 840
Fax: +49 231 9742 844